Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma
نویسندگان
چکیده
منابع مشابه
Clinical biomarkers in esophageal adenocarcinoma.
This review describes genetic and molecular changes related to adenocarcinoma of the esophagus and gastroesophageal junction (GEJ) with emphasis on prognostic value and possibilities for targeted therapy in clinical setting. The progression of Barrett's esophagus to adenocarcinoma has been the focus of particular scrutiny, and a number of potential tissue and serum-based disease biomarkers have...
متن کاملBiomarkers of esophageal adenocarcinoma and Barrett's esophagus.
The rising incidence and poor prognosis of esophageal adenocarcinoma in the Western world have intensified research efforts into earlier methods of detection of this disease and its relationship to Barrett's esophagus. The progression of Barrett's esophagus to adenocarcinoma has been the focus of particular scrutiny, and a number of potential tissue and serum-based disease biomarkers have emerg...
متن کاملEpigenetic Biomarkers: Potential Applications in Gastrointestinal Cancers
Genetics and epigenetics coregulate the cancer initiation and progression. Epigenetic mechanisms include DNA methylation, histone modification, chromatin remodeling, and noncoding RNAs. Aberrant epigenetic modifications play a fundamental role in the formation of gastrointestinal cancers. Advances in epigenetics offer a better understanding of the carcinogenesis and provide new insights into th...
متن کاملPrognostic biomarkers in upper gastrointestinal adenocarcinoma
Estimates indicate that the global cancer burden may be ever-increasing. Gastric cancer is one of the major cancer forms. Despite its declining incidence, the high mortality of gastric cancer makes it the third most common cause of cancer-related death. Esophageal cancer is less common, but the incidence is increasing in parts of the world. Although some progress has been made in the treatment ...
متن کاملCurrent Therapy for Esophageal Adenocarcinoma
Esophageal adenocarcinoma (EAC) affects approximately 17,000 individuals per year in the United States, is increasing in incidence, and is associated with an exceptionally high mortality rate. 1, 2 Overall five-year survival despite aggressive treatment in large, multidisciplinary oncology centers ranges between 15 and 25%. Poor outcome in patients with EAC is reflective of both deficiencies in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Translational Gastroenterology and Hepatology
سال: 2020
ISSN: 2415-1289
DOI: 10.21037/tgh.2020.01.08